Kondo T, Nakatsugawa M, Okubo M, et al. - Researchers here describe the case of a 65-year-old man suffering from laryngeal cancer with multiple lung metastases, in whom a complete response (CR) was maintained for 18 months following cessation of nivolumab treatment, with colitis occurring 5 months post-drug discontinuation. This case showed progression following 1 course of TPF (cisplatin, docetaxel, and 5-fluorouracil) as induction chemotherapy. During radiotherapy, the patient developed multiple lung metastases, and he was deemed platinum refractory; nivolumab therapy was therefore started. He was administered 240 mg/body nivolumab every 2 weeks. Following course 16 of nivolumab treatment, a computed tomography was performed which corroborated a CR. After 6, 7, and 14 months of taking nivolumab, the patient suffered grade 2 thyroid dysfunction, grade 1 interstitial pneumonia, and grade 2 colitis, respectively; treatment was stopped because despite maintaining a CR, interstitial pneumonia developed twice. Five months post- nivolumab cessation, the patient suffered from colitis; nevertheless, a CR was maintained after 18 months.